Salute e Benessere
Prediabetes Market is Projected to Boost at a Moderate Growth Rate by 2034, Predicts DelveInsight | Key Companies - Novo Nordisk, Aphaia Pharma, HighTide Biopharma Pty Ltd, Eli Lilly and Company, Corcept Therapeutics
Discover which therapies are expected to grab the major prediabetes market share @
Prediabetes is a condition characterized by blood sugar levels that are higher than normal but not yet high enough to be diagnosed as type 2 diabetes. It serves as a critical warning sign and a window of opportunity for individuals to take steps to prevent the progression to diabetes. The primary causes of prediabetes include insulin resistance, where the body's cells do not respond effectively to insulin, and the pancreas's inability to produce enough insulin to manage blood sugar levels. Risk factors for developing prediabetes include being overweight, having a sedentary lifestyle, poor dietary habits, a family history of diabetes, and certain health conditions like hypertension and polycystic ovary syndrome (PCOS).
Symptoms of prediabetes are often subtle or non-existent, making it difficult for individuals to recognize the condition. However, some people may experience signs such as increased thirst, frequent urination, fatigue, and blurred vision. Despite the lack of pronounced symptoms, it is crucial to diagnose prediabetes early through appropriate testing. Diagnosis typically involves a fasting plasma glucose test, an oral glucose tolerance test, or an HbA1c test, which measures average blood sugar levels over the past two to three months. Detecting prediabetes early allows for timely lifestyle interventions, including weight loss, increased physical activity, and dietary changes, which can significantly reduce the risk of progressing to type 2 diabetes and improve overall health.
The prediabetes epidemiology section provides insights into the historical and current prediabetes patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted patient trends by exploring numerous studies and views of key opinion leaders.
The prediabetes market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
In addition to adopting a healthy lifestyle, individuals with prediabetes may benefit from various medications aimed at improving insulin function and reducing Impaired Glucose Tolerance (IGT), thereby hindering the progression to type 2 diabetes. Currently, there are no specific treatments for prediabetes; however, medications approved for T2D treatment, such as , are commonly utilized.
functions as an antihyperglycemic agent, enhancing glucose tolerance in individuals with prediabetes or type 2 diabetes by reducing both baseline and after-meal blood sugar levels. It's occasionally prescribed off-label. Metformin achieves this by reducing liver glucose production, intestinal glucose absorption, and by enhancing insulin sensitivity, promoting the uptake and utilization of glucose in peripheral tissues. Another class of medications used for managing these conditions includes orally consumed , which provoke a two- to three-fold increase in plasma insulin response compared to intravenous glucose-induced hyperglycemia. Commonly prescribed GLP-1 receptor agonists such as liraglutide and exenatide are often recommended for individuals with elevated insulin levels (insulin resistance) or those on the brink of developing diabetes.
Subsequently, like act by binding covalently to the catalytic site of DPP-4, resulting in prolonged enzyme inhibition. Lastly, alpha-glucosidase inhibitors, known colloquially as starch blockers, are antidiabetic agents that assist in lowering blood glucose levels after meals. Unlike many other diabetes medications, they do not directly impact insulin secretion or sensitivity. Instead, they work by slowing down the breakdown of carbohydrates present in starchy foods. Commonly prescribed alpha-glucosidase inhibitors for managing prediabetes and T2D include , among others.
To know more about prediabetes treatment guidelines, visit @
The pipeline of prediabetes is not so robust and lacks essential key players. Some of the emerging therapies include , and others.
is exploring the effects of a 2.4 mg subcutaneous injection of in individuals with obesity and prediabetes. This compound functions as a GLP-1 receptor agonist, operating through various mechanisms such as increasing insulin secretion in response to glucose levels, inhibiting glucagon release, and reducing hepatic gluconeogenesis. These actions lead to a decrease in both fasting and postprandial glucose levels.
In May 2024 , Novo Nordisk released findings from the Phase III trial (STEP 10) investigating semaglutide in individuals with obesity and prediabetes. The trial revealed that semaglutide 2.4 mg outperformed the placebo in reducing body weight and returning subjects to normal blood sugar levels, while also showing enhancements in cardiometabolic risk factors.
is currently assessing in a Phase II trial to determine its effectiveness in enhancing glucose tolerance among individuals with prediabetes who exhibit abnormal results in the Oral Glucose Tolerance Test (OGTT) after six weeks of receiving APH-012.
Apart from these the other therapies in the pipeline for prediabetes treatment include
The anticipated launch of these emerging therapies for prediabetes are poised to transform the market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the prediabetes market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about prediabetes drugs in development @
The dynamics of the prediabetes market are expected to change in the coming years. , , and act as market drivers, while T2D drugs, effective in treating prediabetes, highlight an unmet need, as there is for prediabetes, creating an for new therapies to boost the market of the indication.
Furthermore, potential therapies are being investigated for the treatment of prediabetes, and it is safe to predict that the treatment space will significantly impact the prediabetes market during the forecast period. Moreover, the with improved efficacy and a further are expected to drive the growth of the prediabetes market in the 7MM.
However several factors may impede the growth of the prediabetes market. Although awareness has improved from before, many patients are that they have this condition, and often leads to confusion and , potentially affecting the demand for therapeutics as the disease could be controlled by a change in lifestyle; furthermore, might hamper the uptake of novel therapies.
Moreover, prediabetes treatment poses a and disrupts patients' overall well-being and QOL. Furthermore, the prediabetes market growth may be offset by , , , and a . In addition, the about the disease may also impact the prediabetes market growth.
Download the report to understand which factors are driving prediabetes market trends @
report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key prediabetes companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including among others.
report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 2 diabetes companies, including among others.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve
Shruti Thakur
info@delveinsight.com
+14699457679
www.delveinsight.com
Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/prediabetes-market-is-projected-to-boost-at-a-moderate-growth-rate-by-2034-predicts-delveinsight--key-companies---novo-nordisk-aphaia-pharma-hightide-biopharma-pty-ltd-eli-lilly-and-company-corcept-therapeutics-302176483.html